Last reviewed · How we verify
NCT07440485
Aspergillus Infection in Patients Admitted to Hematology Ward
trial in Aspergillus Infection in 193 participants. Currently enrolling.
14 March 2026
Quick facts
| Lead sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 193 |
| Start date | 14 February 2024 |
| Primary completion | 14 March 2026 |
| Estimated completion | 14 March 2026 |
| Sites | 1 location across Italy |
Conditions studied
- Aspergillus Infection — all drugs for Aspergillus Infection →
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Who can join
18 and older, any sex, with Aspergillus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aspergillus is a filamentous mould ubiquitous in the environment and the concentration of its spores in the air varies according to weather conditions and seasons. In this regard, efforts are often made to limit its diffusion in wards where fragile patients are housed (e.g., ICU, Haematology, Oncology, etc.). Indeed, in these patients, Aspergillus infections can present as pulmonary aspergillosis, invasive rhinosinusitis or angio-invasive aspergillosis with significantly high rates of morbidity and mortality, while it rarely causes disease in healthy immunocompetent subjects. Previous studies have established the correlation between nasal carriage of microorganisms and the development of an invasive infectious disease; however, those studies mainly focused on Staphylococci and Candida species. The main target of this study is to investigate the spread of Aspergillus within a hospital ward and analyse the correlation between nosocomial infection and symptom severity in a cohort of frail population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07440485
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fondazione IRCCS Policlinico San Matteo di Pavia trials
Trials by the same sponsor.
- NCT07534007 — Comprehensive Characterization of Immune Response Induced by Adjuvanted Glycoprotein E (gE)-Based Recombinant VAccine Zo · recruiting
- NCT07494344 — Italian Retrospective/Prospective Observational Study on Prosthetic Surgery in Patients With Congenital Coagulation Dise · recruiting
- NCT07356583 — Neonatal Enterovirus Infections in Italy: Virological Characterization, Genomic and Clinical-epidemiological Insights on · recruiting
- NCT07435207 — Thrombotic RIsk FActors in AL-goneurodystrophy · enrolling by invitation
- NCT07263802 — Effect of a Food Supplement on Glycemic Parameters in Patients With Impaired Glucose Metabolism · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07440485 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Policlinico San Matteo di Pavia
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07440485.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing